Search

Displaying results 1701 - 1710 of 7604 in total
  1. Drug

    Difelikefalin

    go.drugbank.com/drugs/DB11938
    ApprovedInvestigational

    [L36420,L36395] Difelikefalin was later approved by the EMA in April 2022 for the same indication.[L41665] … [A237620] Options for therapy are limited - with no FDA-approved treatments, off-label [gabapentin] was the most evidence-based and widely available treatment.

  2. Drug

    Betaine

    go.drugbank.com/drugs/DB06756
    ApprovedInvestigationalNutraceutical

    Currently, no treatments are available to correct the genetic causes of homocystinuria. … [L43105] Although it is present in many food products, the levels found there are insufficient to treat this condition.

    Mixtures: Neo Life Beta Gest TabSynonyms: 2-N,N,N-trimethylammonio acetate, N,N,N-Trimethylglycine
  3. Drug

    Difamilast

    go.drugbank.com/drugs/DB14987
    ApprovedInvestigational

    Atopic dermatitis is a chronic and fluctuating pruritic inflammatory skin condition characterized by pruritic eczema and is also marked by exacerbations and remissions. … The drug is indicated for the topical treatment of mild to moderate atopic dermatitis in adults and pediatric patients 2 years of age and older [L55042]. It is approved in Japan and the United States.

  4. Drug

    Eculizumab

    go.drugbank.com/drugs/DB01257
    ApprovedInvestigational

    [L6919,A2245] Binding to this protein prevents the activation of a complement terminal complex, which is used to treat a number of autoimmune conditions. … [L6919,A2245,A2246] Eculizumab was granted FDA approval on 16 March 2007.

  5. Drug

    Tafamidis

    go.drugbank.com/drugs/DB11644
    ApprovedInvestigational

    Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives[A27206] developed by FoldRX.[A189717] Tafamidis is structurally similar to diflusinal. … [A189717] Tafamidis was granted an EMA market authorisation on 16 November 2011[L6247] and FDA approval on 3 May 2019.[L11280]

  6. Drug

    Mazindol

    go.drugbank.com/drugs/DB00579
    Approved

    Mazindol is a tricyclic anorexigenic agent that is unrelated to and less toxic than [amphetamine], but with some similar side effects. … It inhibits uptake of catecholamines and blocks the binding of cocaine to the dopamine uptake transporter.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  7. Drug

    Delandistrogene moxeparvovec

    go.drugbank.com/drugs/DB16802
    ApprovedInvestigational

    It was granted accelerated approval by the FDA on June 22, 2023, as the first gene therapy to treat Duchenne Muscular Dystrophy (DMD). … [L47026] DMD is an X-linked genetic disorder characterized by mutations in the dystrophin gene, leading to a deficiency in functional dystrophin protein.

  8. Drug

    Methaqualone

    go.drugbank.com/drugs/DB04833
    ApprovedIllicitWithdrawn

    The sedative-hypnotic activity was first noted by Indian researchers in the 1950s and in 1962 methaqualone itself was patented in the US by Wallace and Tiernan. … Clandestinely produced methaqualone is still seized by government agencies and police forces around the world.

  9. Drug

    N-alkyl ethylbenzyl dimethyl ammonium (C12-C14)

    go.drugbank.com/drugs/DB11202
    Approved

    N-alkyl ethylbenzyl dimethyl ammonium (c12-c14) is a quaternary ammonium compound with surfactant properties. … C12-C14 dimethyl ethylbenzyl ammonium chloride is difficult to elucidate.

    Salts: N-alkyl ethylbenzyl dimethyl ammonium chloride (C12-C14)Mixtures: Mevon No. 72 Liq
  10. Drug

    Ceftizoxime

    go.drugbank.com/drugs/DB01332
    ApprovedWithdrawn

    A semisynthetic cephalosporin antibiotic which can be administered intravenously or by suppository. … It has few side effects and is reported to be safe and effective in aged patients and in patients with hematologic disorders.